1. Home
  2. SGML vs PHAT Comparison

SGML vs PHAT Comparison

Compare SGML & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sigma Lithium Corporation

SGML

Sigma Lithium Corporation

HOLD

Current Price

$11.74

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$8.55

Market Cap

969.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGML
PHAT
Founded
2011
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
969.8M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
SGML
PHAT
Price
$11.74
$8.55
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$18.75
$19.83
AVG Volume (30 Days)
1.5M
1.6M
Earning Date
05-13-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
$272.11
$93.04
Revenue Next Year
$36.70
$58.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
216.93
52 Week Low
$4.62
$8.21
52 Week High
$24.48
$18.31

Technical Indicators

Market Signals
Indicator
SGML
PHAT
Relative Strength Index (RSI) 55.68 32.90
Support Level $11.16 N/A
Resistance Level $12.36 $11.85
Average True Range (ATR) 0.59 0.64
MACD 0.34 -0.27
Stochastic Oscillator 94.54 7.20

Price Performance

Historical Comparison
SGML
PHAT

About SGML Sigma Lithium Corporation

Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds full interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil. Geographically, the company operates in Switzerland; United Arab Emirates; Singapore; and Republic of Korea, of which it derives maximum revenue from Switzerland.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: